|
Genomic Expression (c) |
|
DATA™ - Diagnostic Platform for Personalized Medicine |
|
Scientific Advisors
Ulrik Nielsen, Ph.D. Founder and CTO Merrimack Pharmaceuticals. Prior to joining Merrimack, Dr. Nielsen was a post-doctoral fellow in Dr. Peter Sorger's laboratory at the Massachusetts Institute of Technology, where he researched the interface among biology, engineering, and computational biology. Dr. Nielsen received his Ph.D. from the University of Copenhagen in molecular biology and trained in the laboratory of Dr. James D. Marks at the University of California, San Francisco. Dr. Nielsen received an M.S. and a B.S. in biochemistry from the University of Copenhagen.
Charles E. Glatt, Ph.D. Assistant Professor of Psychiatry at The Weill Cornell Medical College. He received his medical degree from The Johns Hopkins University School of Medicine and his Ph.D. thesis in Neuroscience in the laboratory of Solomon H. Snyder also at Johns Hopkins. He completed his Residency training in Psychiatry as well as post-doctoral research training in human genetics at The University of California, San Francisco. His research involves the integration of basic neurobiology and human genetics to understand the molecular basis of behavior and behavioral disorders. He is Principle Investigator or Investigator on several grants that relate to his approach to behavioral genetics supported by NIH, The National Association for Research on Schizophrenia and Affective Disorders (NARSAD), and The Hartwell Foundation.
Professor Niels Tommerup, Ph.D. Professor at Copenhagen University, Department of Cellular and Molecular Medicine (ICMM), Faculty of Health Sciences is head of The Wilhelm Johannsen Centre for Functional Genome Research at Copenhagen University (www.wjc.ku.dk). and predict patient response to particular drugs work is focused on isolation of disease genes by positional cloning/positional candidate gene strategies, by identification and exploitation of disease-associated translocation-breakpoints (Mendelian Cytogenetics) and by combining data on gene expression and biological pathways with genome mapping. Mapping of gene expression/function during normal and abnormal fetal development and during oncogenesis. Gene expression in relation to genomic imprinting/chromosomal structure/position effects. Coordinator of EU-concerted action Mendelian Cytogenetics Network (Biomed 2: 1997-2000). Niels Tommrup’s lab was involved with microRNA research and discovery for both Exiqon and Santaris.
Karen Brøndum-Nielsen, Ph.D. Head of Department, Department of Medical Genetics at The John F. Kennedy (JKI) Institute in Glostrup, Denmark. JKI is the main R&D institute in Denmark, specializing in congenital diseases and genetic counseling. Karen sits on a number of boards, amongst them are the Danish Medical Research Council (they give out R&D grants) and the Board of European Society of Human Genetics. Karen has more than 160published or accepted publications, of which she is first author of more than 50, in addition to more than 110 National and international oral papers and posters. Karen graduated from University of Copenhagen, Medical school 1974, and has held a number of positions within genetics at Hospitals and Universities in Denmark and Sweden, among them Head of Department Clinical Genetics, Karolinska Hospital, Sweden.
Per Guldberg, Ph.D. Per Guldberg is research professor and head of Genomics Laboratory, Institute of Cancer Biology, The Danish Cancer Society. Inventor of a technology for methylation profiling now owned by Epigenomics. He is the author/co-author of 148 original articles and reviews and a patent application.
Business Advisors
|
|
Technology |
|
Contact |
|
Careers |
|
Terms Of Use |